John K. Stroh
President and CEO, Director
Mr. Stroh has over 30 years of experience in senior management, operations, finance, investment banking and M&A, primarily in the medical technology & Life Science fields.  Before joining Nanospectra Mr. Stroh was Interim President and CEO of CryoFem Inc, a Cryoablation company focused in Womens Health.  Prior to that Mr. Stroh was President, CEO and Director of NeoMatrix LLC, a Breast Cancer risk assessment medical device company based in Irvine, California.  From 1984 until 2001, Mr. Stroh worked as a Managing Director and Vice President in the Investment Banking Industry.  During this period, he was instrumental in raising over $1 billion for client companies and consulted on over 100 M&A and strategic partnering transactions.  He is on the Board of Directors for Orange Coast Memorial Hospital and The OCTANe Biomedical Leadership Council.  Mr. Stroh earned a bachelor degree in business from California State University, Long Beach, and also attended the Graduate School of Management at Long Beach State.

Glenn P. Goodrich, PhD
Vice President, Process Development and Chemistry
Dr. Goodrich has been with Nanospectra since 2005.  He holds a BS in Chemistry and a BA in Computer Science from The University of Iowa and a PhD in Chemistry from Penn State University.  He has extensive experience with fabrication and application of nanoparticles, having worked in the field in graduate school and as a post-doctoral fellow under Dr. Naomi Halas at Rice University.

Jon Schwartz, PhD
Director, Clinical Research
Dr. Schwartz has been with Nanospectra since 2005.  He holds a BS and a MS in Electrical Engineering from Rice Universtiy and a PhD in Biophysics from The University of Texas Graduate School of Biomedical Science.  He is responsible for the conduct of Nanospectra's clinical pilot studies for the treatment of human cancers.  Dr. Schwartz’ primary area of research is the development of minimally-invasive tumor ablation techniques using nanoparticles as a means of improving the discrimination between tumor and normal tissue.

Naomi Halas, PhD
Co-Founder
Professor, Rice University
Dr. Halas is the Stanley C. Moore Professor of Electrical and Computer Engineering at Rice University.  She is author of more than 200 refereed publications, has more than ten issued patents, and has presented more than 300 invited talks.  She is known as the inventor of nanoparticles with tunable optical properties controlled by their shape and structure.  She pursues fundamental studies of light-nanoparticle interactions that give rise to new properties and effects, leading to useful applications in biomedicine, chemical sensing, and energy.  She is a Member of the American Academy of Arts and Sciences and a Fellow of the American Physical Society, the Optical Society of America, the International Society for Optical Engineering (SPIE), the Institute for Electrical and Electronics Engineers, and the American Association for the Advancement of Science.

Jennifer West, PhD
Co-Founder, Director
Professor & Chairperson, Rice University

Board of Directors

David Anderson
Chairman of the Board of Directors
Chairman of the Board, PLx Pharma Inc. & Halsa Pharmaceuticals Inc.
Mr. Anderson serves as Chairman on the Board of Directors for Nanospectra Biosciences, Inc. He is also a member of the Board of Directors of PLx Pharma Inc. and Halsa Pharmaceuticals, Inc. and serves as an advisor to other companies in the life sciences industry.  He has over 20 years of experience in the life sciences industry and formerly served as the President and CEO of MithraGen and as the COO and Director of Tanox, Inc.

Patrick W. Pace, MD
Director
Dr. Pace has been on the Board of Directors for Nanospectra since April 2010.  His background includes almost 10 years of financial experience in healthcare.  He currently serves as a Managing Director at Citadel Securities.  Previously, he invested in healthcare for AIG Investments and covered the medical device sector as a Senior Analyst for UBS.  He holds an MD from The University of Texas Medical School - Houston and a BA (Honors in Psychology) from Vanderbilt University.

David Bristol
Director
David Bristol currently serves as an Officer and Director of HCF Enterprises, Inc., a privately held family business responsible for family office operations and investment management in public and private securities, real estate and oil and gas.  He is also a Senior VP and Director of Sentinel Trust Company, LBA, a private trust company serving high net worth clients.  Mr. Bristol has held both of these positions since 1996.  Prior to that, Mr. Bristol had 8 years experience in petroleum exploration and software technology.

John K. Stroh
Director
President and CEO, Nanospectra Biosciences, Inc.

Jennifer West, PhD
Director and Co-Founder
Professor & Chairperson, Department of Bioengineering, Rice University